Clinical Trial Search

Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56 — 89.6; 92.0; -19.3; -19.8 Units on a scale — p=0.935

Primary: Pharmacokinetics of Subcutaneous (SC) PL-3994 Relative to Placebo in Subjects With Controlled Hypertension. — 0; 0.366; 0 ng/mL

Primary: Number of Brain Scans in Healthy Young Adults Subjects Which do Not Show Amyloid — 181; 0; 123; 58 Brain Scans Read

Primary: Percentage Change in Bone Mineral Density (BMD) T-Score From Baseline to 12 Months — 0.08; -0.09 Percentage Change of BMD

Primary: Brief Assessment of Cognition in Affective Disorders (BAC-A) — 0.61; 0.80 units on a scale

Primary: Sum of Pain Intensity Difference (SPID) at Hour 48 — 32.5; 37.2 Units on scale — p=0.1648

Primary: Heterozygous for Filaggrin (FLG) Null Mutations — 1; 4 participants

Primary: Interleukin 1 Beta — 6.18; 2.16; 1.44 pg/mL

Primary: Hypothesize That Subject's Genotype Will Determine How DCA is Metabolized. — 1592; 232 Minutes — p=0.023

Primary: Change in Blood Pressure During High Salt Intake and Fenofibrate Treatment Compared to High Salt Intake and Placebo Treatment — 2.0; -3.4 mm Hg

Primary: Change From Baseline in Visual Analogue Scale (VAS24) Score at Week 4 — 65.80; -22.28 millimeter

Primary: Number of Correct Responses to Questionnaire Items Immediately Before and After and Educational Lecture — 79; 79; 74; 79 participants

Primary: Change in Negative Symptoms — 32.7; 33.5; 31.2; 32.3 units on a scale

Primary: Incidence of Efficacy Failure — 11.4; 13.5 percentage of participants — p=0.341

Primary: Percentage of American College of Rheumatology [ACR] 50 Criteria Responders at Week 12 — 9.9; 23.4; 26.5; 11.4 percentage of participants